« New Study Warns on Increased Risk of Fracture from Nexium - Times Union | Main

Fractures While Taking Fosamax

In October 2010, the U.S. Food and Drug Administration (FDA) updated the label on Fosamax and other bisphosphonates to include the risk of atypical fractures. The agency has published a review in the New England Journal of Medicine after analyzing data from 2,342 post-menopausal women, concluding that there is little evidence to support the use of bisphosphonates for longer than five years.

Another recent study published in the Archives of Internal Medicine examined the risks of femur fractures with bisphosphonate therapy by comparing patients with atypical femur fractures versus classic fractures. Overall, the researchers found that 82 percent of the atypical femur fracture group had been taking bisphosphonates.

July 19, 2012 in Fosamax | Permalink


Post a comment